Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Globally, there are approximately 240 million people chronically infected with hepatitis B virus (HBV)-a major cause of hepatocellular carcinoma. Ten different HBV genotypes (A-J) have been identified with distinct geographic distributions. Novel variants generated by recombination between different HBV genotypes have been documented worldwide and represent an important element of genetic variability with possible clinical implications. Here, the complete genome sequence of an HBV genotype D/E recombinant from Ghana is reported. The full-length sequence was obtained using rolling circle amplification followed by PCR and sequenced using next-generation sequencing (NGS). A consensus sequence was extracted from the NGS data and underwent phylogenetic analysis to determine genotype, as well as the recombination pattern. Subsequently, the sequence was compared to recombinants described previously in Africa. Based on MCMC phylogenetic analysis, SimPlot recombination analyses, and intragroup genetic distance, the isolate 007N full-length genome is unique compared to other reported D/E recombinants in Africa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710801 | PMC |
| http://dx.doi.org/10.1007/s11262-017-1469-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repurposing disulfiram: An innovative inhibitory approach against a broad spectrum of viruses.
Biochem Biophys Res Commun
September 2025
Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China; Department of Pathogen Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandon
Disulfiram (DSF), an FDA-approved therapeutic agent for alcohol dependence, has recently attracted considerable interest due to its broad-spectrum inhibitory effects against various viruses. Increasing evidence suggests that DSF can inhibit viral replication through two major mechanisms: the inhibition of viral protein catalytic activity and the ejection of Zn from viral proteins. This review comprehensively summarized the molecular mechanisms underlying DSF's antiviral activity against viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hepatitis C virus (HCV), influenza virus, human immunodeficiency virus (HIV), and Kaposi sarcoma-associated herpes virus (KSHV), with a particular focus on its dual targeting of Cys residues and Zn coordination sites.
View Article and Find Full Text PDFTrends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024.
J Viral Hepat
October 2025
Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.
View Article and Find Full Text PDFPharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection.
Liver Int
October 2025
Department of Pediatrics and Clinical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Background And Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low- and middle-income countries. WHO guidelines recommend a half-adult dose for children (14-25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17-35 kg.
View Article and Find Full Text PDFComparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer.
Aliment Pharmacol Ther
September 2025
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Background: Current and past hepatitis B virus (HBV) infection remains the leading cause of liver cancer in endemic areas.
Aim: To examine the risk of HBV reactivation (HBVr) in patients receiving immune checkpoint inhibitors (ICI) for liver cancer.
Methods: Patients with current or past HBV infection receiving systemic treatments for liver cancer from March 2015 to March 2023 were identified using a territory-wide electronic database in Hong Kong.
Prevalence of Helicobacter pylori, Salmonella typhi, Plasmodium falciparum, and Toxoplasma gondii infections and levels of liver function markers among Hepatitis B Virus infected Ghanaians: A cross-sectional study in the Greater Accra Region.
PLOS Glob Public Health
September 2025
Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ashanti Region, Ghana.
Coinfection of humans with Hepatitis B Virus (HBV) and non-viral pathogens may worsen the outcome of HBV infection on the liver. This study determined the prevalence of Heliobacter pylori, Salmonella typhi, Plasmodium falciparum, and Toxoplasma gondii among Hepatitis B Virus (HBV)-infected persons in the Greater Accra Region (GAR) of Ghana and examined how such co-infections might affect the levels of selected liver function markers (LFM). The design was cross-sectional, involving 120 HBsAg-positive HBV-infected persons.
View Article and Find Full Text PDF